(19)
(11) EP 4 384 211 A1

(12)

(43) Date of publication:
19.06.2024 Bulletin 2024/25

(21) Application number: 22769884.2

(22) Date of filing: 12.08.2022
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
C07K 14/725(2006.01)
A61P 35/02(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 2039/804; A61P 35/02; C07K 14/7051; C07K 2319/03; A61K 2239/31; A61K 39/4611; A61K 39/464412; A61K 2239/38; A61K 39/464429; A61K 39/464418; A61K 2239/48; A61K 39/4631
(86) International application number:
PCT/EP2022/072693
(87) International publication number:
WO 2023/017159 (16.02.2023 Gazette 2023/07)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 13.08.2021 EP 21191376

(71) Applicant: Ludwig-Maximilians-Universität München
80539 München (DE)

(72) Inventors:
  • GOTTSCHLICH, Adrian
    80337 München (DE)
  • LESCH, Stefanie
    80337 München (DE)
  • ENDRES, Stefan
    80805 München (DE)
  • KOBOLD, Sebastian
    80337 München (DE)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstrasse 3
81675 München
81675 München (DE)

   


(54) ANTI-CSF1R CAR EXPRESSING LYMPHOCYTES FOR TARGETED TUMOR THERAPY